[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 3 sources · 16 days · First seen · Last updated

Prostate cancer PSA level survival research

Overview

Research published in the journal CANCER indicates that achieving a prostate-specific antigen (PSA) level below 0.2 ng/mL within nine months of starting treatment is a significant predictor of survival for patients with metastatic hormone-sensitive (or castration-sensitive) prostate cancer.

Analyzing data from thousands of patients in the United States, the study suggests that this absolute threshold may be a more accurate prognostic indicator than the standard clinical metric of a 90% reduction in PSA levels. While a high percentage of patients achieved a 90% reduction, those who failed to reach the specific 0.2 ng/mL threshold faced higher mortality risks. The findings suggest that PSA levels could serve as a predictive biomarker to help guide personalized and potentially more aggressive treatment strategies.

Entities

American Cancer Society · CANCER Journal · Stephen J. Freedland · National and Kapodistrian University of Athens · Alexandra Hospital

Timeline

  1. 17 days ago

    [HEALTH] 3 sources
    PSA levels below 0.2 ng/mL predict prostate cancer survival

    A study of 4,890 US patients indicates that reaching a PSA level below 0.2 ng/mL within nine months of treatment is a strong predictor of long-term survival in metastatic castration-sensitive prostate cancer.

  2. about 1 month ago

    [HEALTH] 2 sources
    PSA level below 0.2 ng/mL linked to improved prostate cancer survival

    A study of nearly 4,900 patients shows that reaching a PSA level below 0.2 ng/mL within nine months is linked to significantly improved survival in metastatic prostate cancer cases.

Sources

healthmag.gr · ygeiamou.gr · zougla.gr